[
  {
    "ts": "2026-02-26T02:57:26+00:00",
    "headline": "RBC Capital Initiates Bristol Myers (BMY) with $60 Target, Cites Late-Stage Pipeline Depth",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Bristol-Myers Squibb Company (NYSE:BMY) with a Sector Perform rating and a $60 price target. The firm said Bristol Myers has “large-cap pharma’s most significant Phase 3 path,” pointing to […]",
    "url": "https://finance.yahoo.com/news/rbc-capital-initiates-bristol-myers-025726324.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "2c07379b-e4c9-3b35-9afe-678c430b01db",
      "content": {
        "id": "2c07379b-e4c9-3b35-9afe-678c430b01db",
        "contentType": "STORY",
        "title": "RBC Capital Initiates Bristol Myers (BMY) with $60 Target, Cites Late-Stage Pipeline Depth",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Bristol-Myers Squibb Company (NYSE:BMY) with a Sector Perform rating and a $60 price target. The firm said Bristol Myers has “large-cap pharma’s most significant Phase 3 path,” pointing to […]",
        "pubDate": "2026-02-26T02:57:26Z",
        "displayTime": "2026-02-26T02:57:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "RBC Capital Initiates Bristol Myers (BMY) with $60 Target, Cites Late-Stage Pipeline Depth",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w_.mq2hxLlg_y2nUTx72ng--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6o8Kx8kFVS_oEolQVNGNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rbc-capital-initiates-bristol-myers-025726324.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rbc-capital-initiates-bristol-myers-025726324.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T11:59:00+00:00",
    "headline": "SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer",
    "summary": "REDMOND, Wash. & PRINCETON, N.J., February 26, 2026--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treated Unresectable...",
    "url": "https://finance.yahoo.com/news/systimmune-bristol-myers-squibb-highlight-115900249.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "8c58753f-d4f8-33da-9a9d-ce2f5dfa724a",
      "content": {
        "id": "8c58753f-d4f8-33da-9a9d-ce2f5dfa724a",
        "contentType": "STORY",
        "title": "SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer",
        "description": "",
        "summary": "REDMOND, Wash. & PRINCETON, N.J., February 26, 2026--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treated Unresectable...",
        "pubDate": "2026-02-26T11:59:00Z",
        "displayTime": "2026-02-26T11:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a48861f9cd8eb03209aac3a27a67ad9f",
          "originalWidth": 597,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Xr0yHLSpcO7K0u8Ea4V_YQ--~B/aD0yMTc7dz01OTc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a48861f9cd8eb03209aac3a27a67ad9f.cf.webp",
              "width": 597,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/z6myx1Sqqwl_0b5W1NhGrA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a48861f9cd8eb03209aac3a27a67ad9f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/systimmune-bristol-myers-squibb-highlight-115900249.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/systimmune-bristol-myers-squibb-highlight-115900249.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "688506.SS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T14:50:04+00:00",
    "headline": "Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-top-145004493.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d3a9bde9-4f50-33cd-b5a7-ac5189c0c2f0",
      "content": {
        "id": "d3a9bde9-4f50-33cd-b5a7-ac5189c0c2f0",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?",
        "description": "",
        "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
        "pubDate": "2026-02-26T14:50:04Z",
        "displayTime": "2026-02-26T14:50:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4",
          "originalWidth": 900,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/96m3P4v2KypZ_.2vXHQRKA--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4.cf.webp",
              "width": 900,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TvxSS8VO1p90iNVKrfS9eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-top-145004493.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-top-145004493.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T14:38:00+00:00",
    "headline": "RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View",
    "summary": "Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.",
    "url": "https://finance.yahoo.com/news/rvmd-reports-wider-expected-q4-143800232.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f410e3db-9f00-37a3-9dc2-b7ac9d574883",
      "content": {
        "id": "f410e3db-9f00-37a3-9dc2-b7ac9d574883",
        "contentType": "STORY",
        "title": "RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View",
        "description": "",
        "summary": "Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.",
        "pubDate": "2026-02-26T14:38:00Z",
        "displayTime": "2026-02-26T14:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rvmd-reports-wider-expected-q4-143800232.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rvmd-reports-wider-expected-q4-143800232.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "RVMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T11:29:55+00:00",
    "headline": "Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer",
    "summary": "The study result is the latest step forward for a drug Bristol could eventually pay more than $8 billion for and has spotlighted as important to its future growth.",
    "url": "https://www.biopharmadive.com/news/bristol-myers-systimmune-adc-breast-cancer-results-china/813206/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "598ead41-ec80-33be-8a38-92e528e4db25",
      "content": {
        "id": "598ead41-ec80-33be-8a38-92e528e4db25",
        "contentType": "STORY",
        "title": "Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer",
        "description": "",
        "summary": "The study result is the latest step forward for a drug Bristol could eventually pay more than $8 billion for and has spotlighted as important to its future growth.",
        "pubDate": "2026-02-26T11:29:55Z",
        "displayTime": "2026-02-26T11:29:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/0f55ca9bc0fbe54186540b3ef1101105",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Entrance sign of the Bristol Myers Squibb office in Summit, N.J., on Aug. 13, 2023.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IJQri4MCzho5.i9xEywsAg--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/0f55ca9bc0fbe54186540b3ef1101105.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nfhSGu1zO5kfNNiDbePPWA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/0f55ca9bc0fbe54186540b3ef1101105.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/bristol-myers-systimmune-adc-breast-cancer-results-china/813206/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-says-adc-licensed-112955766.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "688506.SS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T21:01:00+00:00",
    "headline": "Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights",
    "summary": "SAN DIEGO, February 26, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.",
    "url": "https://finance.yahoo.com/news/janux-therapeutics-reports-fourth-quarter-210100552.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "94b2dd79-d630-3346-bfe5-825fb313c684",
      "content": {
        "id": "94b2dd79-d630-3346-bfe5-825fb313c684",
        "contentType": "STORY",
        "title": "Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights",
        "description": "",
        "summary": "SAN DIEGO, February 26, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.",
        "pubDate": "2026-02-26T21:01:00Z",
        "displayTime": "2026-02-26T21:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/97ce3086caf804422a9bdcb721d4304a",
          "originalWidth": 480,
          "originalHeight": 254,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6xZAGul51yVKM0Q_mXmcBg--~B/aD0yNTQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/97ce3086caf804422a9bdcb721d4304a.cf.webp",
              "width": 480,
              "height": 254,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iHRQZbo31MzPvjyQ9wrlpQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/97ce3086caf804422a9bdcb721d4304a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/janux-therapeutics-reports-fourth-quarter-210100552.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/janux-therapeutics-reports-fourth-quarter-210100552.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JANX"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T16:10:00+00:00",
    "headline": "ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder Value",
    "summary": "By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Transaction enables exposure to both oral drug delivery program & medical device businesses Oramed Pharmaceuticals (NASDAQ:ORMP) recently signed a binding agreement for a transformative strategic transaction with Lifeward Ltd and another accredited investor. Lifeward is a medical device company focused on devices to aid physical",
    "url": "https://finance.yahoo.com/news/ormp-enabling-participation-both-ormp-161000955.html",
    "source": "Zacks Small Cap Research",
    "provider": "yfinance",
    "raw": {
      "id": "80f728ff-3967-332b-8b69-fd30a5b3382a",
      "content": {
        "id": "80f728ff-3967-332b-8b69-fd30a5b3382a",
        "contentType": "STORY",
        "title": "ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder Value",
        "description": "",
        "summary": "By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Transaction enables exposure to both oral drug delivery program & medical device businesses Oramed Pharmaceuticals (NASDAQ:ORMP) recently signed a binding agreement for a transformative strategic transaction with Lifeward Ltd and another accredited investor. Lifeward is a medical device company focused on devices to aid physical",
        "pubDate": "2026-02-26T16:10:00Z",
        "displayTime": "2026-02-26T16:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Zacks Small Cap Research",
          "url": "http://scr.zacks.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ormp-enabling-participation-both-ormp-161000955.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ormp-enabling-participation-both-ormp-161000955.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LFWD"
            },
            {
              "symbol": "ORMP"
            },
            {
              "symbol": "MDT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]